Event Description
Advances in gene therapies for monogenic disorders have brought hope of curative treatment. Since the Food and Drug Administration first approved a gene therapy in 2017, the pipeline has steadily increased such that 20 new gene therapies are expected to be approved each year starting soon. Health system decision makers around the world are facing complex issues related to value, affordability, and equity posed by the high upfront cost of these new therapies. Traditional health economics approaches to assess value are intricately linked to values, the normative aspects of resource allocation decisions. This panel presentation will provide an overview of pragmatic and ethical aspects of health technology assessment (HTA) and payment models for gene therapies from an international perspective.
Event Information:
Free and open to the public; registration required. For more information, please visit the event webpage.
Hosted by the Center for ELSI Resources and Analysis at Columbia University as part of the ELSI Friday Forum series.
